Paratek Pharmaceuticals (PRTK) Stock Price, News & Analysis

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" PRTK shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in PRTK, but not buy additional shares or sell existing shares.
View PRTK analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 1 year target prices for Paratek Pharmaceuticals' stock. Their PRTK share price targets range from $2.15 to $5.00. On average, they anticipate the company's stock price to reach $3.58 in the next year. This suggests a possible upside of 60.3% from the stock's current price.
View analysts price targets for PRTK or view top-rated stocks among Wall Street analysts.

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) posted its quarterly earnings data on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.08. The specialty pharmaceutical company had revenue of $24.45 million for the quarter, compared to the consensus estimate of $22.98 million. During the same period in the prior year, the company earned ($0.46) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), CBL & Associates Properties (CBL), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Aduro Biotech (ADRO), Corbus Pharmaceuticals (CRBP) and Rigel Pharmaceuticals (RIGL).